<DOC>
	<DOCNO>NCT00404573</DOCNO>
	<brief_summary>This study design evalute safety efficacy RGH-188 treatment acute schizophrenia . This study 10 week duration ; 6 week double-blind treatment , 4 week safety follow-up . All patient meet eligibility criterion randomize one three treatment group -- one two dose RGH-188 placebo</brief_summary>
	<brief_title>Study Evaluating RGH-188 Treatment Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Male female inpatient , 1865 year age , meet DSMIVTR criterion schizophrenia Total Positive Negative Syndrome Scale ( PANSS ) Score &gt; =80 &lt; =120 . A score &gt; =4 item P1 ( delusion ) P3 ( hallucinatory behavior ) score &gt; =4 item P2 ( conceptual disorganization ) P6 ( suspiciousness/persecution ) PNASS Patients document disease central nervous system interfere trial assessment , include limited stroke , tumor , Parkinson 's , organic brain disease , seizure disorder ( except febrile convulsion infancy ) , chronic infection , neurosyphilis ; patient suffer traumatic brain injury result significant impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>